Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'
Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on BillionToOne, and calls Eton Pharma a winner.
Read original at benzingaStocks · News reference
Canaccord Genuity Initiates Coverage On Eton Pharmaceuticals with Buy Rating, Announces Price Target of $60
Canaccord Genuity analyst Gary Nachman initiates coverage on Eton Pharmaceuticals (NASDAQ:ETON) with a Buy rating and announces Price Target of $60.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 17, 2026, 10:24 AM
- Checked
- Jul 17, 2026, 10:24 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
Eton Pharmaceuticals announced record Q2 2026 revenue with product sales of $37.6 million, representing 99% year-over-year growth. The company reported GAAP EPS of $0.35 and non-GAAP EPS of $0.43, with EBITDA of $14.1 million. Additionally, Eton expanded its infantile hemangioma franchise by acquiring U.S. rights to ASN-001, a late-stage product candidate targeting moderate infantile hemangiomas, complementing its existing HEMANGEOL product.
Read original at globenewswire-incDow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone
The Fear & Greed Index, which measures market sentiment, declined while remaining in the Greed zone. U.S. stocks closed lower, with the Dow Jones falling over 100 points.
Read original at benzingaCanaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $68
Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $60 to $68.
Read original at benzinga